Although several small-scale studies have suggested potential benefits of GLP-1 RAs on liver histology, current guidelines (EASL–EASD–EASO and AASLD) do not recommend GLP-1 agonists specifically for the treatment of MASH. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.